Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
Hernández-Boluda JC, Pereira A, Cervantes F, Gómez M, Arellano-Rodrigo E, Alvarez-Larrán A, Ferrer-Marín F, Kerguelen A, Márquez JA, Antelo ML, Besses C; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Hernández-Boluda JC, et al. Among authors: besses c. Ann Hematol. 2013 Jun;92(6):771-5. doi: 10.1007/s00277-013-1683-7. Epub 2013 Jan 26. Ann Hematol. 2013. PMID: 23354997
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.
Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, Martínez-Avilés L, Navarro B, Teruel A, Martínez-Ruiz F, Besses C. Hernández-Boluda JC, et al. Among authors: besses c. Br J Haematol. 2011 Jan;152(1):81-8. doi: 10.1111/j.1365-2141.2010.08430.x. Epub 2010 Nov 18. Br J Haematol. 2011. PMID: 21083657 Free article.
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C. Alvarez-Larrán A, et al. Among authors: besses c. Blood. 2012 Feb 9;119(6):1363-9. doi: 10.1182/blood-2011-10-387787. Epub 2011 Dec 12. Blood. 2012. PMID: 22160617 Free article.
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C. Alvarez-Larrán A, et al. Among authors: besses c. Ann Hematol. 2014 Dec;93(12):2037-43. doi: 10.1007/s00277-014-2152-7. Epub 2014 Jul 2. Ann Hematol. 2014. PMID: 24981691 Clinical Trial.
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larrán A, Gómez M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Hernández-Boluda JC, et al. Among authors: besses c. Ann Hematol. 2015 Jun;94(6):911-8. doi: 10.1007/s00277-015-2330-2. Epub 2015 Feb 14. Ann Hematol. 2015. PMID: 25680896
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC, Pereira A, Cervantes F, Alvarez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy B, Maffioli M, Bellosillo B, Marugán I, Amat P, Besses C, Guillem V. Hernández-Boluda JC, et al. Among authors: besses c. Blood. 2012 May 31;119(22):5221-8. doi: 10.1182/blood-2012-02-411215. Epub 2012 Apr 11. Blood. 2012. PMID: 22496165 Free article. Clinical Trial.
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Hernández-Boluda JC, Pereira A, Gómez M, Boqué C, Ferrer-Marín F, Raya JM, García-Gutiérrez V, Kerguelen A, Xicoy B, Barba P, Martínez J, Luño E, Alvarez-Larrán A, Martínez-López J, Arbelo E, Besses C; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas. Hernández-Boluda JC, et al. Among authors: besses c. Haematologica. 2014 Apr;99(4):e55-7. doi: 10.3324/haematol.2013.101733. Epub 2014 Jan 31. Haematologica. 2014. PMID: 24488561 Free PMC article. No abstract available.
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.
Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, Pérez-Encinas M, Ferrer-Marín F, Bárez A, Martínez-López J, Cuevas B, Mata MI, García-Gutiérrez V, Aragües P, Montesdeoca S, Burgaleta C, Caballero G, Hernández-Rivas JA, Durán MA, Gómez-Casares MT, Besses C; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Alvarez-Larrán A, et al. Among authors: besses c. Br J Haematol. 2016 Mar;172(5):786-93. doi: 10.1111/bjh.13886. Epub 2015 Dec 21. Br J Haematol. 2016. PMID: 26898196 Free article.
193 results